WiseGuyReports.Com Publish a New Market Research Report On –“ U.S. Influenza Industry Pipeline Review and Outlook 2023”.
Influenza is an upper respiratory tract disease and is caused by the influenza virus. Influenza virus is mainly three types namely Influenza A, Influenza B, and Influenza C. Influenza is a communicable disease, spread through a flu cough, droplets from the infected people, sneeze or talks. The common symptoms occur in influenza patients are chills, cough, running nose, sore throat, body aches, headache, fatigue, some cases people may have vomiting and diarrhea. The complication of the disease may include ear infections, bacterial pneumonia, dehydration, sinus infections, and sometimes it leads to congestive heart failure, and asthma. Influenza commonly occurs in geriatric population and children with less than 5 years of age. The infection may be confirmed by testing the sputum, nose, or throat for the virus. A number of rapid tests are available however polymerase chain reaction that detects the virus’s RNA is more accurate.
The U.S. Influenza market is growing at a significant CAGR due to rise in newborn babies, an increase in geriatric population. Increase in vaccination awareness, favorable reimbursement scenario, and rising investment by companies in research and development activities are the major factors fuelling the growth of U.S. influenza market over the forecast period. The major market players have great pipeline products, initiatives by government bodies such as WHO and CDC to control and prevent influenza, technological advancements in diagnostic tests also fuel the growth of U.S. influenza market over the forecast period. However, limited production capacity, a high level of required investment, and stringent regulatory policies for new product approvals might hamper the growth of U.S. Influenza market. Due to limitations in current technologies, the lengthy production times (approximately seven months), increase in prices of influenza diagnostic kits and reagents also hinder the U.S. Influenza market.
For more information or any query mail at [email protected]
The U.S. Influenza market is segmented on the basis of product type, distribution channel, and end user
Based on drug class, U.S. influenza market is segmented into the following:
Based on the route of administration, U.S. influenza market is segmented into the following:
Based on distribution channel U.S. influenza market is segmented into the following:
Influenza vaccines are key revenue contributor for the growth of U.S. influenza market. The U.S. influenza market is in growing phase, several international players are actively involved in the development of vaccines and drugs to treat influenza. The launch of new products, technological innovations, and approvals from U.S. Food and Drug Administration (FDA) for various drugs might fuel the growth of U.S. influenza market. For instance, Squires used both egg and cell-based technologies to offer the broadcast portfolio of influenza vaccines in the U.S. for both trivalent and quadrivalent formulations. Similarly, transformative changes in other vaccine markets, due to the entrance of expensive and innovative vaccines such as Gardasil (Merck) and Bexsero (GSK) are projected to contribute growth of the U.S. influenza market.
U.S. holds a dominant share in the global influenza market. The largest share is attributed to the higher rate of in-vitro diagnostics availability and technological advancements in medical devices which are primarily driving the U.S. Influenza market growth. As per CDC, persons above 6 months of age could be vaccinated to prevent the influenza infection. Increase in prevalence and incidence cases of influenza (According to CDC, about 5 to 20 percent of the U.S. people are infected with influenza in every year. CDC also states that about 200,000 people hospitalized and more than 36,000 people are dying from influenza in U.S) might increase the growth of U.S. influenza market. Similarly, the upsurge in funding by the government is also driving the market growth in the United States. The U.S. government awarded 5-year contracts for more than US$ 1 Bn to five drug manufacturers developing technology for speedier mass production of influenza vaccines
Some of the players in U.S. influenza market are AstraZeneca (U.K.), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Sanofi (France), Seqirus (U.K.), Protein Sciences Corporation (U.S.), Emergent Biosolutions (U.S.), BioCryst Pharmaceuticals.Inc (U.S.)., Alvogen (South Korea), Medimmune Inc. (U.S.), DynPort Vaccine Company, LLC. (U.S.), and Abbott Laboratories (U.S.) to name a few.
In May 2016, Seqirus received approval from U.S. Food and Drug Administration for Flucelvax Quadrivalent, that was the first U.S. licensed cell-based quadrivalent influenza vaccine indicated for people aged four years and older
In November 2016, GSK received approval from U.S. Food and Drug Administration for flulaval Quadrivalent to include use in children aged six months or older
The report provides granular level information about the market size, regional market share, and forecast from 2017-2023
The report covers in-detail insights about the competitor’s overview, key findings, and their key strategies
The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
The report tracks recent innovations, key developments and startup’s details that are working in the industry
The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
Table Of Contents – Major Key Points
1. Executive summary
2. U.S. Influenza Market Introduction
2.1. U.S. Influenza Market – Taxonomy
2.2. U.S. Influenza Market –Definitions
2.2.1. Drug Class Type
2.2.2. Route of Administration
2.2.3. Distribution Channel
3. U.S. Influenza Market Dynamics
3.3. Opportunities/Unmet Needs of the Market
3.5. U.S. Influenza Market Dynamics – Factors Impact Analysis
3.6. U.S. Influenza Market – Regulations
3.7. U.S. Influenza Market – Product Innovations
4. U.S. Influenza Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. U.S. Influenza Market, By Drug Class, 2012 - 2016 and Forecast, 2017 - 2023
5.1. Anti Viral Drugs
18.104.22.168. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
22.214.171.124. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
126.96.36.199. Market Opportunity Analysis
188.8.131.52. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
184.108.40.206. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
220.127.116.11. Market Opportunity Analysis
For more information or any query mail at [email protected]
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.
P: +44 208 133 9349
M: +1 646 845 9349